{"title":"Effectiveness and safety of sarilumab in polymyalgia rheumatica: A retrospective study of the FIRST registry.","authors":"Naoaki Ohkubo, Yusuke Miyazaki, Satoshi Kubo, Ippei Miyagawa, Koshiro Sonomoto, Yoshino Inoue, Yurie Satoh-Kanda, Hiroaki Tanaka, Masanobu Ueno, Atsushi Nagayasu, Takafumi Aritomi, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Kiyotake Yoshioka, Mayu Nishimoto, Kazuki Takahashi, Shingo Nakayamada, Yoshiya Tanaka","doi":"10.1093/mr/roag030","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the effectiveness of sarilumab in patients with polymyalgia rheumatica (PMR) who were clinically assessed as having coexisting rheumatoid arthritis.</p><p><strong>Methods: </strong>Using data from the FIRST registry, a cohort of patients initiating molecular targeted therapy for rheumatoid arthritis, we identified cases from 2003 to April 2024 in which sarilumab was introduced as the first biologic agent and PMR was concurrently diagnosed. As a control group, we selected patients hospitalized for a PMR flare during the same period who received the standard of care without biologic therapy. The primary outcome was the clinical PMR Activity Score at 52 weeks post-treatment initiation.</p><p><strong>Results: </strong>Among 5645 registered cases, 67 patients were identified as having PMR with coexisting rheumatoid arthritis and received sarilumab as their initial biologic therapy. The control group comprised 76 patients treated with conventional therapy alone. The 52-weeks continuation rate of sarilumab was 77.5%, indicating high treatment persistence. At 52 weeks, clinical PMR Activity Score scores decreased in both groups. Logistic regression analysis using low disease activity at 52 weeks as the outcome revealed sarilumab use as a significant predictor. After adjusting for baseline differences using inverse probability weighting based on propensity scores, the sarilumab group showed a significantly greater reduction in the clinical PMR Activity Score compared to the standard of care group.</p><p><strong>Conclusions: </strong>These findings suggest that sarilumab may have the potential to improve disease activity in polymyalgia rheumatica compared to conventional therapy.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"1046-1054"},"PeriodicalIF":2.1000,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mr/roag030","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To evaluate the effectiveness of sarilumab in patients with polymyalgia rheumatica (PMR) who were clinically assessed as having coexisting rheumatoid arthritis.
Methods: Using data from the FIRST registry, a cohort of patients initiating molecular targeted therapy for rheumatoid arthritis, we identified cases from 2003 to April 2024 in which sarilumab was introduced as the first biologic agent and PMR was concurrently diagnosed. As a control group, we selected patients hospitalized for a PMR flare during the same period who received the standard of care without biologic therapy. The primary outcome was the clinical PMR Activity Score at 52 weeks post-treatment initiation.
Results: Among 5645 registered cases, 67 patients were identified as having PMR with coexisting rheumatoid arthritis and received sarilumab as their initial biologic therapy. The control group comprised 76 patients treated with conventional therapy alone. The 52-weeks continuation rate of sarilumab was 77.5%, indicating high treatment persistence. At 52 weeks, clinical PMR Activity Score scores decreased in both groups. Logistic regression analysis using low disease activity at 52 weeks as the outcome revealed sarilumab use as a significant predictor. After adjusting for baseline differences using inverse probability weighting based on propensity scores, the sarilumab group showed a significantly greater reduction in the clinical PMR Activity Score compared to the standard of care group.
Conclusions: These findings suggest that sarilumab may have the potential to improve disease activity in polymyalgia rheumatica compared to conventional therapy.
期刊介绍:
Modern Rheumatology publishes original papers in English on research pertinent to rheumatology and associated areas such as pathology, physiology, clinical immunology, microbiology, biochemistry, experimental animal models, pharmacology, and orthopedic surgery.
Occasional reviews of topics which may be of wide interest to the readership will be accepted. In addition, concise papers of special scientific importance that represent definitive and original studies will be considered.
Modern Rheumatology is currently indexed in Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed/Medline, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, EBSCO, CSA, Academic OneFile, Current Abstracts, Elsevier Biobase, Gale, Health Reference Center Academic, OCLC, SCImago, Summon by Serial Solutions